Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionBallentine Partners, LLC
Latest Disclosed Ownership5,247 shares
Latest Disclosed Value $ 2,343,218
Ballentine Partners, LLC reports 0.81% decrease in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 14, 2026 - Ballentine Partners, LLC filed a 13F-HR form disclosing ownership of 5,247 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $2,342,995 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 3, 2026 disclosing 5,290 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of -0.81% during the quarter. The current value of the position is $2,344,517 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,247 -43 -0.81 2,343 -2.29 0.0229
2026-02-03 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,290 200 3.93 2,398 20.32 0.0337
2025-11-03 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 5,090 -338 -6.23 1,993 -17.51 0.0277
2025-07-15 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 5,428 -409 -7.01 2,417 -14.60 0.0364
2025-05-01 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,837 247 4.42 2,830 25.68 0.0491
2025-01-16 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,590 119 2.18 2,251 -11.52 0.0386
2024-10-23 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 5,471 123 2.30 2,544 1.52 0.0435
2024-08-06 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 5,348 470 9.64 2,507 22.90 0.0464
2024-04-11 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,878 309 6.76 2,039 9.68 0.0387
2024-01-23 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,569 201 4.60 1,859 22.46 0.0379
2023-10-19 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 4,368 892 25.66 1,519 24.12 0.0357
2023-07-26 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,476 131 3.92 1,223 16.14 0.0281
2023-04-27 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,345 893 36.42 1,054 48.73 0.0265
2023-01-27 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,452 436 21.63 708 21.23 0.0210
2022-10-26 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,016 504 33.33 584 37.09 0.0202
2022-08-09 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,512 -148 -8.92 426 17.03 0.0151
2022-02-14 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,660 1,660 364 0.0109
2021-10-27 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -1,023 -100.00 0 -100.00
2021-08-12 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,023 -84 -7.59 206 -13.45 0.0071
2021-05-11 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,107 -128 -10.36 238 -18.21 0.0088
2021-01-25 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,235 -227 -15.53 291 -26.88 0.0115
2020-10-22 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,462 16 1.11 398 -5.24 0.0176
2020-07-31 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,446 -49 -3.28 420 17.98 0.0201
2020-04-23 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,495 84 5.95 356 15.21 0.0207
2020-01-22 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,411 58 4.29 309 34.35 0.0140
2019-10-21 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,353 -8 -0.59 230 -8.00 0.0108
2019-07-25 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,361 1,361 250 0.0120
2018-02-02 2017-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -1,825 -100.00 0 -100.00
2017-11-06 2017-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,825 -3 -0.16 277 -6.10 0.0153
2017-08-03 2017-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,828 1,828 295 0.0215
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.